Upjohn Co. said its profit rose 20%...
Upjohn Co. said its profit rose 20% in the third quarter to $89.6 million, largely attributable to sales of its baldness medication Rogaine. The Kalamazoo, Mich.-based pharmaceutical products firm did not give specific sales figures, but said Rogaine led major products in foreign sales growth and received new marketing approvals during the quarter in several countries.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
